![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
PHARMACOKINETIC MODELING OF ACH-2684, A HEPATOSELECTIVE
PHASE I PAN-GENOTYPIC HCV NS3 PROTEASE INHIBITOR:
PREDICTIONS AND CORRELATION WITH HUMAN
PHARMACOKINETICS
|
|
|
Reported by Jules Levin
AASLD Nov 5-9 2011 SF
Kathe Stauber, Elizabeth Olek, Jose Rivera, Christopher Marlor,
Lisa Robarge, Minjung Huang, Avinash Phadke, and Milind Deshpande
Achillion Pharmaceuticals, Inc. New Haven, CT 06511, USA
![AASLD1.gif](../images/111011/111011-7/AASLD1.gif)
![AASLD2.gif](../images/111011/111011-7/AASLD2.gif)
![AASLD3.gif](../images/111011/111011-7/AASLD3.gif)
![AASLD4.gif](../images/111011/111011-7/AASLD4.gif)
![AASLD5.gif](../images/111011/111011-7/AASLD5.gif)
![AASLD6.gif](../images/111011/111011-7/AASLD6.gif)
![AASLD7.gif](../images/111011/111011-7/AASLD7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|